07:00 , Apr 19, 2010 |  BC Week In Review  |  Company News

GenWay Biotech, Radient Pharmaceuticals sales and marketing update

GenWay received an exclusive five-year license to market, sell and distribute Radient's Onko-Sure test in Greece. The in vitro diagnostic test measures fibrin and fibrinogen degradation products in the bloodstream. Financial terms were not disclosed....
07:00 , Oct 26, 2009 |  BC Week In Review  |  Company News

Radient Pharmaceuticals, University of Chile deal

Radient's AMDL Diagnostics Inc. subsidiary and the university will develop AMDL's diagnostic Onko-Sure (formerly DR-70) for lung cancer. The university will provide samples and conduct clinical validation testing of the in vitro cancer diagnostic, which...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Company News

Grifols, Radient Pharmaceuticals sales and marketing update

Under a five-year deal, Radient's AMDL Diagnostics Inc. subsidiary granted Grifols' Grifols USA LLC subsidiary exclusive rights to market Onko-Sure (formerly DR-70) in the U.S. to monitor colorectal cancer. The test detects the level of...
07:00 , Aug 24, 2009 |  BC Week In Review  |  Company News

AMDL diagnostic news

AMDL said it plans to shift its focus from distributing pharmaceuticals in China to developing and commercializing its marketed in vitro cancer diagnostic Onko-Sure (formerly DR-70) and its Elleuxe skin care products. The company also...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Financial News

AMDL completes private placement of notes and warrants

AMDL Inc. (NYSE-A:ADL), Tustin, Calif.   Business: Diagnostic   Date completed: 6/15/09   Type: Private placement of notes and warrants   Raised: $468,500   Placement agent: Cantone Research   Note: AMDL raised $468,000 in the...
07:00 , May 25, 2009 |  BC Week In Review  |  Company News

AMDL, GenWay Biotech sales and marketing update

GenWay Biotech received exclusive rights to market and distribute AMDL's DR-70 cancer test to CLIA-certified laboratories in the U.S. and laboratories in Canada for five years. GenWay has rights to market and distribute DR-70 for...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Clinical News

DR-70 ELISA regulatory update

FDA granted 510(k) clearance for AMDL's ELISA DR-70 test to detect the progression of colorectal cancer following surgery. AMDL said that the agency also issued a letter of substantial equivalence for the in vitro immunoassay...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Company News

AMDL, MyGene Co. Ltd. sales and marketing update

AMDL received an exclusive license to manufacture, market and distribute MyGene's MyHPV Chip Kit for in vitro testing for genital human papillomavirus (HPV) in Taiwan, Singapore, Malaysia, Thailand, Cambodia, Vietnam and China, including Hong Kong....
07:00 , Oct 22, 2007 |  BC Week In Review  |  Clinical News

DR-70 ELISA regulatory update

ADL submitted a 510(k) application to FDA for its DR-70 ELISA test as an aid in monitoring patients previously diagnosed with colorectal cancer. The in vitro immunoassay kit detects the level of fibrin-fibrinogen degradation product...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Clinical News

DR-70 regulatory update

AMDL received marketing approval in South Korea for DR-70, a non-invasive immunoassay kit to detect 13 different types of cancer from blood samples. AMDL Inc. (ADL), Tustin, Calif.   Product: DR-70   Business: Diagnostic  ...